Hematologic Malignancy
Indolent B-Cell Non-Hodgkin Lymphoma
CI-CAN-00005561Explore in graph →
Hematologic172 active trials6 approved drugs2 evidence items
- NCIt
- C171299
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005561Explore in graph →
Clinical trials
617 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (109)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05990465 | LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | recruiting | Phase 1 | 12 | Medical College of WisconsinOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | recruiting | Phase 1 / Phase 2 | 32 | Vironexis Biotherapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07744750 |
| Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma |
| not yet recruiting |
| Phase 2 |
| 40 |
| Changzhou No.2 People's HospitalOTHER |
| 1 |
| Aug 6, 2026 |
| clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT06708897 | A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies | recruiting | Phase 1 | 84 | Lomond Therapeutics Holdings, Inc.INDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | recruiting | Phase 1 | 180 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Jul 30, 2026 | clinicaltrials |
| NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | recruiting | Phase 1 / Phase 2 | 92 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07459608 | Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma | not yet recruiting | Phase 2 | 75 | Henan Cancer HospitalOTHER_GOV | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04333524 | FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role(PIMENTO) | active not recruiting | — | 496 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Jul 24, 2026 | clinicaltrials |
| NCT07121946 | This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | recruiting | Phase 1 | 42 | LTZ Therapeutics, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04212013 | A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma | active not recruiting | Phase 3 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT01479842 | Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 | 48 | Kami Maddocks, MDOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05735834 | Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients(RITZ) | active not recruiting | Phase 3 | 122 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 8 | Jul 22, 2026 | clinicaltrials |
| NCT06471738 | Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma | recruiting | Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07713459 | A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | not yet recruiting | Phase 2 | 105 | Kure Cells, INCINDUSTRY | 0 | Jul 20, 2026 | clinicaltrials |
| NCT05024045 | Study of Oral LOXO-338 in Patients With Advanced Blood Cancers | completed | Phase 1 | 27 | Eli Lilly and CompanyINDUSTRY | 4 | Jul 17, 2026 | clinicaltrials |
| NCT07711327 | Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy | not yet recruiting | — | 500 | Tina BaykanerOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT02494700 | Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07705308 | A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma | not yet recruiting | Phase 2 | 140 | Ruijin HospitalOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | terminated | Phase 1 | 51 | BeOne MedicinesINDUSTRY | 4 | Jul 14, 2026 | clinicaltrials |
| NCT06043011 | Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms(RUBIN) | recruiting | — | 2,950 | iOMEDICO AGINDUSTRY | 1 | Jul 13, 2026 | clinicaltrials |
| NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment | not yet recruiting | Phase 2 | 138 | SWOG Cancer Research NetworkNETWORK | 0 | Jul 13, 2026 | clinicaltrials |
| NCT05665062 | Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies | active not recruiting | Phase 1 | 36 | SynthekineINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT06300528 | Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas | active not recruiting | Phase 2 | 1 | University of UtahOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT03269669 | Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma | active not recruiting | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | active not recruiting | Phase 2 / Phase 3 | 422 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07420959 | ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia | not yet recruiting | Phase 1 / Phase 2 | 38 | Mayo ClinicOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT04416451 | A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma | active not recruiting | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT05131022 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | recruiting | Phase 1 | 572 | Nurix Therapeutics, Inc.INDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT02339922 | Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma | active not recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06860880 | Combating Cancer-Related Fatigue: A Personalized Supportive Care Program | recruiting | N/A | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05653271 | ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | completed | Phase 1 | 16 | Acepodia Biotech, Inc.INDUSTRY | 3 | Jun 30, 2026 | clinicaltrials |
| NCT06905509 | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | recruiting | Phase 2 | 25 | University of California, DavisOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT01209871 | Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma | completed | Phase 1 | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT02520791 | Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma | active not recruiting | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2026 | clinicaltrials |
| NCT04205409 | Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01815749 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04257578 | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07664787 | Safety and Efficacy of Renal Denervation for Untreated Grade I Hypertension: a Pilot Study(STAR) | not yet recruiting | N/A | 20 | Ruijin HospitalOTHER | 0 | Jun 24, 2026 | clinicaltrials |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | active not recruiting | Phase 1 / Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04545762 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | recruiting | Phase 1 | 36 | C. Babis AndreadisOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05700149 | Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | recruiting | — | 300 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 15 | Jun 22, 2026 | clinicaltrials |
| NCT07376330 | Molecular and Cellular Characterization of MALT Lymphoma | not yet recruiting | — | 400 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07592481 | Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors(HEMO-CONNECT) | not yet recruiting | N/A | 40 | Centre Hospitalier de la côte BasqueOTHER | 0 | Jun 22, 2026 | clinicaltrials |
| NCT06636175 | 64Cu-LLP2A for Imaging Hematologic Malignancies | recruiting | Early Phase 1 | 42 | Washington University School of MedicineOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07231952 | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07654465 | Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma(ROMA) | not yet recruiting | Phase 2 | 144 | Sun Yat-sen UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 6, 2026source: clinicaltrials